$DKS — AVOID 📊 | 6 MONTHS THESIS

$DKS — AVOID 📊 | 6 MONTHS THESIS 🧭 Conviction: HIGH 🎯 FQ1 FY2027 (ends Apr) | reported May 27 | Rev $5.2B | EPS $2.90 vs $3.08 🔴 | Margin 8.7% 💡 Consensus expected EPS of $3.08 but the company reported $2.90 (-5.8% miss). The market is still pricing the stock at 20.6x trailing earnings, well above the sector base of 14.7x, implying overly optimistic growth that isn't materializing. 🏢 Business Quality: 4 — Moderate brand in consumer discretionary with thin 8.7% operating margin, negative FCF, and leveraged balance sheet (net debt of ~$908M)./10 📊 Valuation: rich — at 20.6x trailing P/E vs peer range 8.0x-14.7x-27.6x, the stock is above fair value; DCF implies negative equity value given negative FCF;... 🔮 Catalyst: Next quarterly earnings report ⚖️ Avoid DKS — earnings miss, negative FCF, and rich valuation with no catalyst for upside; risk of severe multiple compression outweighs any short-term bounce.

🧭 Conviction: HIGH